The Importance of Anticipating Risk
This article was originally published in SRA
Three months ago, in May 2006, the US Food and Drug Administration (FDA) asked manufacturers of attention deficit hyperactivity disorder drugs to strengthen the warnings on the labels of their products to highlight the risk of serious cardiovascular and psychiatric events. Similarly, in 2004, the agency asked manufacturers of anti-depressants to add boxed warnings to their products about the increased risk of suicidal behaviour in children and adolescents. One might reasonably ask, “Why now?” Most of these drugs have been on the market for years (in one case more than 20 years) and in some cases prescribed to very large numbers of people, including for off-label use. The answer is that until recently, the regulatory community didn't look at the risk profile of a drug over time and in the context of different users. Now it does. And it's about time.
You may also be interested in...
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.